eli lilly gip/glp-1 GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 drmcgowan was just featured in

I passionately believed in the molecule and its potential for both diseases, and I have continued to be a part of the unfolding scientific narrative surrounding GLP-1 over those 35 years

A licensed provider will review your medical history and determine if treatment is appropriate for you

If our ancestors brains didnt urge them to eat ravenously, whenever an opportunity arose they probably didnt live long enough to pass along their genes

PsA Disease Activity Improves on GLP-1s A retrospective study presented at ACR Convergence 2025, led by researchers from the University of Toronto and NYU, followed 48 patients with psoriatic arthritis who started GLP-1 receptor agonists. The findings: Significant weight loss (35% of patients lost 510% of body weight

By integrating claims with clinical data, researchers can find insights that were previously hidden

GLP-1 weight loss medications have created unprecedented demand for abdominal contouring procedures in 2026